Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy.

BACKGROUND: IgE titres tend to rise early after the start of immunotherapy, followed by a decline to pre-immunotherapy levels or lower. OBJECTIVES: We were interested to know whether the early increase in IgE antibodies includes new specificities of IgE, and whether these responses persist. METHODS: Sera of 64 patients undergoing grass pollen immunotherapy were tested for IgE against four purified grass pollen allergens: Lol p 1, 2, 3, and 5. At least two serum samples were taken, one before the start of therapy and one between 5 and 18 months after the first immunization (mean: 10 months). RESULTS: The mean IgE responses to Lol p 1, 2 and 3 showed a moderate but not significant increase. In contrast, the mean IgE response to Lol p 5 showed a significant decrease of > 30%. IgE against total Lohum perenne pollen extract moderately increased (> 20%), showing that a RAST for total pollen is not always indicative for the development of IgE against its major allergens. For > 40% of the patients it was found that IgE against one or more of the four allergens increased, while IgE against the remaining allergen(s) decreased. For 10 sera the ratio of IgE titres against at least two allergens changed by at least a factor of 5. The changes in specific IgE also included conversions from negative (< 0.1 RU) to positive (0.6 to 5.0 RU) for five patients. For two patients, the induction of these 'new' IgE antibodies against major allergens was shown to result in a response that was persistent over several years. CONCLUSION: Although active induction of new IgE specificities by immunotherapy was not really proven, the observations in this study indicate that monitoring of IgE against purified (major) allergens is necessary to evaluate changes in specific IgE in a reliable way.

A double-blind clinical trial wtih cromoglycate eye drops in patients with atopic conjunctivitis.

In a group of 33 typical hay fever patients with apparent conjunctivitis a double-blind clinical trial was carried out during the summer of 1978. One group of patients used 2% cromoglycate eye drops and the other group used placebo eye drops, both in sterile unit-dose packages without benzalconium hydrochloride. Symptoms and use of other symptomatic treatment were recorded daily. The mean daily scores were compared with the daily pollen counts. The daily records of symptoms were somewhat lower in the cromoglycate than in the placebo group, though not significantly so. Mean daily scores of symptoms correlated with the pollen counts fairly well. Need of symptomatic medication did not differ in either groups and had no relation to the pollen counts. Although a beneficial effect had been expected, cromoglycate eye drops were considered ineffective in this study.